Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
NEW YORK, April 27, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its first quarter 2017 financial results prior to the NASDAQ market open on Thursday, May 4, 2017. Intercept management will conduct a conference call and audio webcast on Thursday, May 4, 2017 at 8:30 a.m. Eastern Time to discuss these results.
Intercept management will also be presenting at the following investor conference:
- Bank of America Merrill Lynch 2017 Healthcare Conference on May 17, 2017 at 5:00 p.m. Pacific Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
